The US FDA has recently approved several significant cancer therapies, marking notable advancements in the treatment of various forms of cancer. Tislelizumab, developed by BeiGene, has been approved for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy, a decision celebrated by the medical community as it represents the first U.S. approval for this medicine under the brand name TEVIMBRA. Similarly, Lisocabtagene Maraleucel, also known as Breyanzi, received approval for treating relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with Bristol Myers winning accelerated approval for this first CAR-T therapy for adults. Additionally, the FDA's Oncologic Drugs Advisory Committee (ODAC) has unanimously supported the benefit-risk profile of Cilta-Cel for early relapsed or refractory myeloma, and expanded use of Bristol Myers' CAR-T therapy has been endorsed. Despite concerns about early deaths, FDA advisers have also backed J&J and Legend's Carvykti for earlier myeloma treatment. These approvals and recommendations highlight the FDA's ongoing commitment to advancing cancer treatment options.
An FDA advisory committee has backed Carvykti and Abecma for use in earlier lines of treatment, but the real takeaway from the meeting is that it's time to prioritize rapid CAR T manufacturing https://t.co/h4zm8WXNSJ
UPDATED: Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma https://t.co/ZDET1nhTsW
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy https://t.co/TN4OrUBSl9 https://t.co/OAhuFyMX8f
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma https://t.co/egWxVZ0DTc @ByJonGardner $JNJ $BMY $LEGN
BeiGene finally snags FDA approval for PD-1 drug Tevimbra after long delay, Novartis breakup https://t.co/k7nQj8FRzw
Despite early death concerns, FDA advisers back J&J and Legend's Carvykti for earlier myeloma https://t.co/ZDET1nhTsW
Bristol Myers nabs new FDA nod as Breyanzi brings CAR-T class to chronic lymphocytic leukemia https://t.co/UiZ8saZMpg
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy https://t.co/6ym07yYs2B https://t.co/af4Jij0t0f
Another win for CAR T - #FDA approval for #Breyanzi in CLL and SLL, a win for patients https://t.co/GOpZVBRibC https://t.co/24gPHtcQvU
FDA ODAC Committee Votes Unanimously in Favor of Benefit-Risk Profile of Cilta-Cel in Early R/R Myeloma https://t.co/wygBesUVLq via @onclive
Bristol Myers cell therapy wins first-of-its-kind approval https://t.co/E8AGysp9V7 $BMY by @realJacobBell
Bristol Myers cell therapy wins first-of-its-kind approval https://t.co/Ud8y4myfes vby @realJacobBell $BMY $ALLO
Geron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug https://t.co/jWCDIjX021
$GERN up 85%. Here's my take on yesterday's imetelstat adcom, via @ApexOnco -> https://t.co/fC9yRxaKLA
Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia https://t.co/gZOFbfCI1M
$BMY FDA Approves Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma
$BGNE BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - https://t.co/9qSDDCnkiD It is its its first US clearance after a series of setbacks
US FDA expands use of Bristol Myers' cancer therapy https://t.co/YPb2mxfmIS https://t.co/64DbdX9mQa
Bristol Myers won accelerated approval for the first CAR-T therapy for adults with two forms of hard-to-treat leukemia or lymphoma https://t.co/kGBIwb1rqd
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL https://t.co/0MOBCjLNw6 via @onclive
Proud to share the FDA approved our PD-1 inhibitor for the treatment of advanced or metastatic esophageal squamous cell carcinoma (#ESCC) after prior chemotherapy. This is the first approval of this medicine in the U.S. and an important part of our efforts to help more patients. https://t.co/RmnPIFnaDZ
US FDA approves BeiGene's esophageal cancer therapy https://t.co/DZo7klTVoA https://t.co/fU1WbbCmw8
An advisory committee has just greenlighted a Bay Area company's drug for blood cancer patients. Here's the latest. https://t.co/ziIgtLXITb
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy https://t.co/0QMK5QVVxX via @onclive
BREAKING: @US_FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy #esocsm #oncology https://t.co/CHlrBg83mJ https://t.co/SzzaIsXw2G